Catalio Capital Management

Asset Manager

New York, New York, US

Description

Catalio Capital Management is a multi-strategy investment firm specializing in breakthrough biomedical technology and healthcare innovation. Founded in 2020, the company invests in life sciences companies globally, targeting drugs, devices, diagnostics, and data-driven insights. Catalio leverages its network of world-class scientists and clinicians to identify and grow transformative technologies from inception to exit.

Recent Transactions involving Catalio Capital Management

Deal	Target	Platform	Buyer	Industry
QIA invests in Ensoma, a genomic medicines company	Ensoma		Bill & Melinda Gates Foundation Strategic Investment Fund Arix Bioscience Solasta Ventures F-Prime Capital Takeda Ventures SymBiosis Alexandria Venture Investments Fred Hutchinson Cancer Center Qatar Investment Authority Catalio Capital Management Mirae Asset Financial Group Cormorant Asset Management Viking Global Investors	Biotechnology Research

Deal

Target

Platform

Buyer

Industry

QIA invests in Ensoma, a genomic medicines company

Ensoma

Bill & Melinda Gates Foundation Strategic Investment Fund

Arix Bioscience

Solasta Ventures

F-Prime Capital

Takeda Ventures

SymBiosis

Alexandria Venture Investments

Fred Hutchinson Cancer Center

Qatar Investment Authority

Catalio Capital Management

Mirae Asset Financial Group

Cormorant Asset Management

Viking Global Investors

Biotechnology Research

The Lower and Middle Market M&A Platform

See how PrivSource can help you close more deals.

Learn more →